ARAY

No open position. Record a trade on the Portfolio tab and it flows into this card.

2x. 5% effective rate and ongoing covenant risk. The peer-based Stage 1 valuation is unreliable due to balance-sheet distress and thin margins; a distressed valuation range is required.

Generated by deepseek-v4-flash. Advisory only — every flag is logged against the rule that raised it for the review loop.

• 8-KJun 04, 2026Item 1.02,7.01

  Source ↗

  Accuray repaid the remaining $18.0 million of its 3.75% Convertible Senior Notes at maturity on June 1, 2026, using cash on hand, eliminating its last major debt obligation. The filing contains no operational or strategic updates.

  Show extraction ▾Hide extraction ▴

  MD&A highlights

  • ·Repaid remaining $18.0 million aggregate principal of 3.75% Convertible Senior Notes due 2026 on June 1, 2026, plus $337,500 accrued interest; Indenture satisfied and discharged.

  Extracted by deepseek-v4-flash · Jul 22, 2026

• 10-QMay 06, 2026

  Source ↗

  Accuray's Q3 fiscal 2026 results reflect deteriorating financial performance, with a net loss of $11.8 million for the quarter and $47.3 million year-to-date, driven by lower revenue, margin compression from supply chain and inflation headwinds, restructuring charges of $15.4 million, and a surge in interest expense to $24.2 million. The company ended the period with $44.4 million in cash and equivalents, but operating cash flow was negative $9.4 million. Debt stood at $145.2 million net, with a 24.5% effective interest rate on its Term Loan Facility, and the company faces ongoing covenant compliance risk. Management provided cautious near-term guidance, expecting continued margin and cash flow pressure through fiscal 2026. The restructuring plan and sale of tariff refund claims for $6.6 million provide modest relief. Key risks include Nasdaq minimum bid price non-compliance, covenant breaches, and prolonged U.S. market weakness.

  Show extraction ▾Hide extraction ▴

  MD&A highlights

  • ·Total net revenue decreased to $301.0 million for the nine months ended March 31, 2026 from $331.0 million in the prior year period.
  • ·Gross profit decreased to $76.4 million from $108.0 million.
  • ·Operating loss of $32.0 million compared to operating income of $3.6 million.
  • ·Restructuring charges of $15.4 million incurred in fiscal 2026.
  • ·Interest expense increased to $24.2 million from $8.7 million due to higher debt and PIK interest.
  • ·Net cash used in operating activities was $9.4 million compared to net cash provided of $12.6 million.

  Guidance

  The Company expects that gross margins and net income (loss) will continue to be adversely affected by increased material costs and freight and logistics expenses through at least fiscal year 2026. It expects inflation and supply chain challenges to impact cash from operations through at least fiscal year 2026. Reduced U.S. budgets and longer installation timelines are expected to continue impacting revenue through fiscal year 2026. Total restructuring charges for the FY26 Restructuring Plan are expected to be approximately $17 million, substantially all paid in cash in fiscal 2026.

  Backlog

  As of March 31, 2026, total remaining performance obligations amounted to $70.2 million, of which $53.6 million relates to warranty performance obligations. The Company expects to recognize the significant majority of the additional $16.6 million of remaining performance obligations (primarily deferred training and system installations) over the next 12 months. Open system orders, upgrade sales orders, and customer credits are excluded from these balances because they do not meet the definition of a remaining performance obligation under ASC 606.

  Debt / leverage

  As of March 31, 2026, total debt net was $145.2 million, comprising a $148.8 million Term Loan Facility, $5.0 million drawn on a Revolving Credit Facility, $18.0 million of Convertible Senior Notes due June 1, 2026, and $7.7 million of accumulated paid-in-kind interest. The weighted-average effective interest rate on the Term Loan Facility was 24.5%. The Financing Agreement includes financial covenants (fixed charge coverage ratio, leverage ratio, minimum liquidity); failure to comply could accelerate debt and require replacement financing. The Company sold $9.0 million of IEEPA tariff refund claims for $6.6 million in cash after quarter end.

  Key risks

  • ·Adverse impacts from geopolitical and macroeconomic conditions including inflation, high interest rates, foreign currency fluctuations, tightening credit markets, conflicts in Iran/Middle East/Russia-Ukraine, and U.S.-China tensions.
  • ·Supply chain challenges and increased component and logistics costs negatively affecting gross margins and cash flows through at least fiscal 2026.
  • ·Reduced U.S. capital deployment for radiotherapy equipment and longer installation timelines impacting revenue through fiscal 2026.
  • ·Potential non-compliance with Nasdaq minimum bid price rule and risk of delisting.
  • ·Risk of non-compliance with debt covenants in the Financing Agreement, which could accelerate repayment and require new financing.

  Forward-looking · richest in 10-Ks

  Outlook / tone

  Based on the balance of cash and cash equivalents, available debt facilities, current business plan and revenue prospects, the Company believes it will have sufficient cash resources and anticipated cash flows to fund its operations for at least the next 12 months. However, the Company expects ongoing adverse impacts from geopolitical and macroeconomic conditions, supply chain disruptions, inflation, and reduced U.S. capital deployment for radiotherapy equipment through at least fiscal year 2026.

  Strategic priorities

  • ·Implementation of the FY26 Restructuring Plan to reduce global workforce by approximately 18% cumulatively and lower operating costs, with estimated total charges of $17 million.

  Extracted by deepseek-v4-flash · Jul 22, 2026

• 8-KMay 06, 2026Item 2.02,7.01,9.01

  Source ↗

  Accuray filed an 8-K on May 6, 2026, reporting fiscal Q3 2026 results and withdrawing its full-year fiscal 2026 guidance. The filing includes a press release and an investor presentation, but no specific operational or financial details are provided in the 8-K itself. The withdrawal of guidance suggests near-term uncertainty.

  Show extraction ▾Hide extraction ▴

  Guidance

  Withdrawn for fiscal year 2026.

  Forward-looking · richest in 10-Ks

  Outlook / tone

  The company withdrew its financial guidance for fiscal year 2026.

  Extracted by deepseek-v4-flash · Jul 22, 2026

• 8-KApr 07, 2026Item 1.01,9.01unprocessed

  Source ↗

  Facts ingested; qualitative extraction pending.

• 10-KFeb 17, 2026

  Source ↗

  Accuray's fiscal 2025 10-K/A reveals a company facing persistent operational and macro headwinds: U.S. hospital budget constraints and longer installation cycles are expected to pressure revenue through 2026, while supply chain and inflation continue to weigh on margins and cash flow. The restatement of RPO from $818M to $61M underscores significant disclosure weaknesses and resulted in material internal control deficiencies. Debt levels remain substantial with $188M in borrowings plus $18M in convertible notes, and past covenant compliance issues highlight refinancing risk. Despite these challenges, the absence of MD&A in this filing limits insight into management's near-term playbook. Strategic priorities and capital allocation plans are not explicitly articulated, though the company remains focused on international expansion and product development. Overall, the tone is cautious, with multiple risk factors flagging tariff exposure, IT security, and competitive threats.

  Show extraction ▾Hide extraction ▴

  Guidance

  Management expects reduced budgets and longer customer installation timelines in the U.S. to continue impacting net revenue through fiscal year 2026, and expects inflation and supply chain challenges to impact cash from operations through at least calendar year 2025.

  Backlog

  The Company restated its remaining performance obligations (RPO) from $818.2 million to $60.9 million as of June 30, 2025, primarily due to incorrect inclusion of open system orders, upgrade sales orders, and customer credits as RPO. Backlog conversion remains subject to long installation cycles and customer financing delays.

  Debt / leverage

  As of June 30, 2025, the Company had $150 million term loan, $20 million revolving credit facility, $20 million delayed draw term loan (all maturing June 6, 2030), and $18.0 million of 3.75% Convertible Senior Notes due 2026. The credit facilities contain restrictive covenants including fixed charge coverage ratio and total leverage ratio. The Company has not been in compliance with certain similar covenants in the past and required waivers.

  Key risks

  • ·If the CyberKnife or TomoTherapy platforms do not achieve widespread market acceptance, we will not be able to generate the revenue necessary to support our business.
  • ·We have substantial indebtedness and may incur other debt in the future, which may adversely affect our financial condition and future financial results.
  • ·Enhanced international tariffs, including tariffs imposed by the United States and China, other trade barriers or a global trade war could decrease the volume of product sales in China and increase our costs.
  • ·We have identified material weaknesses in our system of internal controls as of June 30, 2025 and are in the process of remediation.
  • ·Disruption of critical information technology systems, infrastructure and data or cyberattacks or other security breaches or incidents could harm our business and financial condition.

  Forward-looking · richest in 10-Ks

  Outlook / tone

  Management's tone is cautious and hedged, citing ongoing headwinds from reduced U.S. hospital capital budgets, longer installation timelines, supply chain disruptions, and tariff uncertainty. For example, they state 'we expect this will continue to have an impact through fiscal year 2026' and note that 'we cannot assure you that we will be able to achieve profitability.' The filing also highlights material weaknesses in internal controls, further tempering confidence.

  Capital allocation

  The credit agreement restricts the Company's ability to pay dividends or make other distributions. No share buyback programs or M&A appetite are mentioned.

  Risk-factor changes

  The risk factors were amended to include a new risk regarding material weaknesses in internal control over financial reporting identified after the original filing, specifically related to the review of footnote schedules and inadequate controls for RPO disclosure under ASC 606.

  Extracted by deepseek-v4-flash · Jul 22, 2026

• negativemedium magnitudenear-termmanual2d ago

  Owner note: channel checks suggest China install timing slips into Q4

  Consistent with sub-1.0 book-to-bill; near-term revenue risk but does not change the installed-base thesis.

  ApproveReject